Renovorx reports third quarter 2024 financial results and operational highlights

Near-term revenue potential with commercialization plan for fda-cleared renovocath® delivery system in both direct and commercial partner channels renowned clinical oncology sites participating in ongoing pivotal phase iii tiger-pac clinical trial; trial moving towards next interim analysis and full enrollment as of september 30, 2024, the company had $9.6 million in cash, sufficient to fund operations to achieve next interim read-out and fund current renovocath commercialization efforts los altos, calif., nov. 14, 2024 (globe newswire) -- renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing novel targeted oncology therapies and offering renovocath, a novel, fda-cleared local drug-delivery platform, today announced its financial results and operational highlights for the third quarter ended september 30, 2024.
RNXT Ratings Summary
RNXT Quant Ranking